Show simple item record

dc.contributor.authorWhitehead, Michael
dc.contributor.authorWickremasinghe, Sanjeewa
dc.contributor.authorOsborne, Andrew
dc.contributor.authorVan Wijngaarden, Peter
dc.contributor.authorMartin, Keith R
dc.date.accessioned2018-12-13T00:32:58Z
dc.date.available2018-12-13T00:32:58Z
dc.date.issued2018-12
dc.identifier.issn1471-2598
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/286856
dc.description.abstractINTRODUCTION: Diabetic retinopathy (DR) is the leading cause of vision loss in the working age population of the developed world. DR encompasses a complex pathology, and one that is reflected in the variety of currently available treatments, which include laser photocoagulation, glucocorticoids, vitrectomy and agents which neutralize vascular endothelial growth factor (VEGF). Whilst these options demonstrate modest clinical benefits, none is yet to fully attenuate clinical progression or reverse damage to the retina. This has led to an interest in developing novel therapies for the condition, such as mediators of angiopoietin signaling axes, immunosuppressants, nonsteroidal anti-inflammatory drugs (NSAIDs), oxidative stress inhibitors and vitriol viscosity inhibitors. Further, preclinical research suggests that gene therapy treatment for DR could provide significant benefits over existing treatments options. AREAS COVERED: Here we review the pathophysiology of DR and provide an overview of currently available treatments. We then outline recent advances made towards improved patient outcomes and highlight the potential of the gene therapy paradigm to revolutionize DR management. EXPERT OPINION: Whilst significant progress has been made towards our understanding of DR, further research is required to enable the development of a detailed spatiotemporal model of the disease. In addition, we hope that improvements in our knowledge of the condition facilitate therapeutic innovations that continue to address unmet medical need and improve patient outcomes, with a focus on the development of targeted medicines.
dc.description.sponsorshipCambridge Eye Trust Research Councils UK - Medical Research Council the Wellcome Trust
dc.format.mediumPrint-Electronic
dc.languageeng
dc.publisherInforma UK Limited
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectAnimals
dc.subjectHumans
dc.subjectDiabetic Retinopathy
dc.subjectAngiogenesis Inhibitors
dc.subjectGlucocorticoids
dc.subjectTherapies, Investigational
dc.subjectGenetic Therapy
dc.titleDiabetic retinopathy: a complex pathophysiology requiring novel therapeutic strategies.
dc.typeArticle
prism.endingPage1270
prism.issueIdentifier12
prism.publicationDate2018
prism.publicationNameExpert Opin Biol Ther
prism.startingPage1257
prism.volume18
dc.identifier.doi10.17863/CAM.34162
dcterms.dateAccepted2018-11-05
rioxxterms.versionofrecord10.1080/14712598.2018.1545836
rioxxterms.versionAM
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2018-12
dc.contributor.orcidWhitehead, Michael [0000-0002-5494-8302]
dc.contributor.orcidMartin, Keith [0000-0002-9347-3661]
dc.identifier.eissn1744-7682
rioxxterms.typeJournal Article/Review
pubs.funder-project-idCambridge Eye Trust (unknown)
pubs.funder-project-idMedical Research Council (1944187)
cam.issuedOnline2018-11-14
cam.orpheus.successThu Jan 30 10:53:34 GMT 2020 - The item has an open VoR version.
rioxxterms.freetoread.startdate2100-01-01


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International